GEN-MKT-18-7897-A
Aug 4, 2023 | Blogs, Echo® MS+ system, Pharma | 0 comments
Read Time: 2 minutes
Bringing a new drug to market is a costly and complex process. With potentially hundreds of thousands of new compounds to screen during drug discovery, sample throughput is a common bottleneck for pharmaceutical companies. So how do you overcome this barrier?
The challenges Let’s dig a little deeper into some of the related organizational challenges. On average, the development time for a new drug is 10–15 years, and Deloitte recently reported that the average cost of approving a new pharmaceutical for clinical use rose to $2.3 billion in 20221. Since approximately 90% of new drug candidates fail during development, the ability to make early, informed and accurate decisions about the safety and efficacy of new leads is key to saving time, reducing costs and maximizing success.
The solution The Echo® MS system, which can provide accurate mass spectrometry data in seconds, can help ease these challenges. Based on Acoustic Ejection Mass Spectrometry (AEMS), this system removes the need for chromatographic separation, which increases analytical speed without compromising data quality.
This free infographic explores the concepts of AEMS-based workflows, and the benefits of using this approach for efficient and rapid lead optimization of drug candidates. For example:
Curious to know more? Learn more by exploring the following content, where data from the instrument is used to demonstrate what the system offers.
Rapid MS/MS analysis with Acoustic Ejection Mass Spectrometry (AEMS)
The Echo® MS system from SCIEX breaks through bottlenecks in quantitative mass spectrometry throughput. This technical note describes a rapid, chromatography-free approach to MS/MS analysis and showcases the potential of AEMS to dramatically change the field of high-throughput analysis.
High-throughput metabolite quantification for synthetic biology
This technical note shares a quantitative approach for the screening of 90 yeast strains to monitor over 60 metabolites. This workflow demonstrates the ability of the Echo® MS system to rapidly screen a biological matrix for key metabolites of interest with significantly reduced analysis times.
References
Echo® and Echo® MS are trademarks or registered trademarks of Labcyte, Inc. in the United States and other countries, and are being used under license.
Finding the right information shouldn’t slow you down. Whether you’re troubleshooting your mass spec, learning something new, or optimizing performance, access to the right resources at the right moment makes all the difference.
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
Posted by
You must be logged in to post a comment.
Share this post with your network